[New post] 23andMe obtient une autorisation de mise sur le marché témoignant de l’avancement de la FDA dans la réglementation des tests génétiques (23andMe obtains authorization for placing on the market reflecting the progress of the FDA in the regulation of genetic tests)

New post on The Science Office 23andMe obtains authorization for placing on the market reflecting the progress of the FDA in the regulation of genetic tests by Hocine Lourdani On February 19, the "Food and Drug Administration" (FDA) granted 23andMe a marketing authorization (MA) opening a new chapter in the regulation of screening methods made ​​possible by advances exponentially around the genetic sequencing [1]. The test in question allows the detection port of the recessive allele of a gene responsible Bloom's syndrome, a rare genetic disease causing stunted growth and increased risk of developing cancer. It is particularly suitable for future parents, if both would be from Central or Eastern Europe, especially among Ashkenazi Jewish families. This is the first genetic test directly for the general public, without the need to go through a health professional. 23andMe and all the industry players can look forward to such a decision, reflecting the willingness of the US authorities to facilitate the emergence of such tests and accompany the genomic revolution in the industry. Read more in the Electronic Bulletins . Hocine Lourdani | March 1, 2015 at 10:19 pm | Tags: brief , breve_FR , Hocine Lourdani | Categories: Article , big data , genetics , health , innovation , Life Sciences , Science | URL:http://wp.me/p2qe5n-43o How See all comments